DeepMed Research

Royal Marsden NHS Foundation Trust

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.royalmarsden.nhs.uk

Clinical Trials

Randomised Study to Investigate the Effectiveness of Acupuncture for the Relief of Long COVID-19 Related Fatigue

Phase 2

Completed

Conditions: COVID-19

Interventions: Other: Active Control
Other: Acupuncture

First Posted Date: 2022-01-28

Last Posted Date: 2024-10-18

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 119

Registration Number: NCT05212688

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

Evaluation of New Magnetic Resonance Techniques

Recruiting

Conditions: Magnetic Resonance Imaging

First Posted Date: 2021-11-12

Last Posted Date: 2021-11-29

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 2850

Registration Number: NCT05118555

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence

Conditions: Head and Neck Squamous Cell Carcinoma

First Posted Date: 2021-10-01

Last Posted Date: 2021-10-08

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 500

Registration Number: NCT05065086

Locations: 🇬🇧
The Royal Marsden Hospital, London, United Kingdom

Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Diagnostic Test: ctDNA

First Posted Date: 2021-09-27

Last Posted Date: 2023-06-22

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 400

Registration Number: NCT05058183

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Chelsea, London, United Kingdom
🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Sutton, United Kingdom

Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and CApsular Contracture

Recruiting

Conditions: Capsular Contracture, Implant
Breast Implant-Associated Anaplastic Large Cell Lymphoma
Breast Implant; Complications

First Posted Date: 2021-08-23

Last Posted Date: 2023-01-19

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 100

Registration Number: NCT05017337

Locations: 🇬🇧
Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧
The Royal Marsden NHS Foundation Trust, London, United Kingdom

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Phase 2

Recruiting

Conditions: ER+ Breast Cancer
HER2-negative Breast Cancer

Interventions: Drug: Tamoxifen
Drug: Palbociclib 125Mg Tab
Drug: Fulvestrant injection
Drug: Letrozole
Drug: Exemestane
Drug: Anastrozole

First Posted Date: 2021-08-02

Last Posted Date: 2024-12-05

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 1100

Registration Number: NCT04985266

Locations: 🇬🇧
Barnet Hospital, London, Barnet, United Kingdom
🇬🇧
Royal Sussex Hospital, Brighton, United Kingdom
🇬🇧
Velindre Cancer Centre, Cardiff, United Kingdom

and more 45 locations

Improving Diagnosis and Treatment of Metastatic Advanced Prostate Cancer

Conditions: Advanced Prostate Carcinoma

First Posted Date: 2021-07-30

Last Posted Date: 2021-07-30

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 50

Registration Number: NCT04984395

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

'Lung Health Check' Biomarker Study

Conditions: Lung Cancer
Cancer

Interventions: Diagnostic Test: Blood Specimen

First Posted Date: 2021-07-12

Last Posted Date: 2022-07-18

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 1000

Registration Number: NCT04957433

Locations: 🇬🇧
The Royal Brompton NHS Foundation Trust, London, United Kingdom

Changes to Function and Quality of Life and Patient Experience for Patients Undergoing Treatments for Recurrent Oropharyngeal Cancer

Active, not recruiting

Conditions: Recurrent Oropharynx Carcinoma

First Posted Date: 2021-07-07

Last Posted Date: 2024-08-09

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 25

Registration Number: NCT04952922

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, London, United Kingdom

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer
ER+ Breast Cancer
Advanced Breast Cancer

Interventions: Drug: Ipatasertib 300mg
Drug: Fulvestrant 500g
Drug: CDK4/6 Inhibitor
Drug: Palbociclib 75mg-125mg

First Posted Date: 2021-06-10

Last Posted Date: 2023-10-27

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 324

Registration Number: NCT04920708

Locations: 🇬🇧
Royal Cornwall Hospital, Truro, Cornwall, United Kingdom
🇬🇧
Mount Vernon Cancer Centre, London, Surrey, United Kingdom
🇬🇧
Royal Free Hospital, London, United Kingdom

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy